Effects of a novel infant formula on weight gain and body composition of infants: The INNOVA 2020 study

Julio Plaza-Diaz[1,2,3,#], Francisco Javier Ruiz-Ojeda[1,2,4,5,#], Javier Morales[6], Ana Isabel Cristina de la Torre[7], Antonio García-García[8,9], Cristóbal Coronel[10], Cyntia Crespo[10], Gema García-Ron[11], Ignacio Galicia[8], Marcos Maroto[8], Paola Ruiz[12], Raquel Martín[13], Susana Viver-Gómez[14] and Angel Gil[1,2,5,15,*]

[1]Department of Biochemistry and Molecular Biology II, School of Pharmacy, University of Granada, 18071, Granada, Spain

[2]Instituto de Investigación Biosanitaria IBS.GRANADA, Complejo Hospitalario Universitario de Granada, Granada 18014, Spain

[3]Children's Hospital of Eastern Ontario Research Institute, Ottawa, ON K1H 8L1, Canada.

[4]RG Adipocytes and Metabolism, Institute for Diabetes and Obesity, Helmholtz Diabetes Center at Helmholtz Center Munich, Neuherberg, 85764 Munich, Germany.

[5]Institute of Nutrition and Food Technology "José Mataix", Centre of Biomedical Research, University of Granada, Avda. del Conocimiento s/n. 18016 Armilla, Granada, Spain

[6]Product Development Department, Alter Farmacia SA, 28880 Madrid, Spain.

[7]CS Presentación sabio. C/Alonso Cano 8, 28933 Móstoles, Madrid

[8]Instituto Fundación Teófilo Hernando (IFTH). Parque científico de Madrid. UAM.. C/ Faraday 7. Edificio CLAID. 28049. Madrid.

[9]Departamento de Farmacología, Facultad de Medicina, Universidad Autónoma de Madrid, Madrid, Spain

[10]CS Amante Laffón. Pz San Martín de Porres 8, 41010, Madrid.

[11]CS La Rivota. C/ de las Palmeras s/n, 28922 Alcorcón, Madrid.

[12]CS Las Américas, Av. De América 6, 28983 Parla, Madrid.

[13]CS Doctor Luengo Rodríguez, C/ Nueva York 16, 28938 Móstoles, Madrid.

[14]CS Valle de la Oliva. C/ Enrique Granados 2, 28222 Majadahonda, Madrid.

[15]CIBEROBN (CIBER Physiopathology of Obesity and Nutrition), Instituto de Salud Carlos III, 28029 Madrid, Spain

[#]Equally contributed

* Correspondence:
Prof. Angel Gil

Department of Biochemistry and Molecular Biology II, School of Pharmacy, University of Granada,
Campus de Cartuja s/n, 18071, Granada, Spain

Phone: +34 695466922
agil@ugr.es

Abstract

Background: Breastmilk is the most appropriate food for infants and exclusive breastfeeding is highly
recommended for the first six months of life to promote adequate growth and development and lower
infant morbidity and mortality. Among the best-documented benefits of breastfeeding is the reduced
risk of disease and infections such as pneumonia, diarrhea and acute otitis media. Nonetheless, there
are situations in which the infant cannot be breastfed; therefore, it is essential to use an appropriately
designed infant formula. As current infant formulas incorporate novel ingredients to partly mimic the
composition of human milk, the safety and suitability of each specific infant formula should be tested
by clinical evaluation in the target population. Here, we report the results of a multicenter, randomized,
blinded, controlled clinical trial that aimed to evaluate a novel starting formula on weight gain and
body composition of infants up to 6 and 12 months (INNOVA 2020 study), as well as safety and
tolerability. The complete protocol of this study has been previously issued. **Study design**: 210 infants
(70/group) were enrolled in the study, and completed the intervention until 12 months of age. For the
intervention period, infants were divided into three groups: group 1 received the formula 1 (Nutribén®
Innova1 or INN), with a lower amount of protein, and enriched in α-lactalbumin protein, and with a
double amount of docosahexaenoic acid (DHA)/ arachidonic acid (ARA) than the standard formula; it
also contained a thermally inactivated postbiotic (*Bifidobacterium animalis* subsp. *lactis*, BPL1™ HT).
Group 2 received the standard formula or formula 2 (Nutriben® Natal or STD) and the third group was
exclusively breastfed for exploratory analysis and used as a reference (BFD group). During the study,
visits were made at 21 days, 2, 4, 6, and 12 months of age, with ± 3 days for the visit at 21 days of age,
± 1 week for the visit at 2 months, and ± 2 weeks for the others. During the first 6 months of the study,
and until obtaining the main variable, the infants were only supplied with the starting formula or natural
breastfeeding. **Results**: The primary outcome, weight gain, was higher in both formula groups than in
the BFD group at 6 and 12 months, whereas no differences were found between STD and INN groups
neither at 6 nor at 12 months. Likewise, BMI was higher in infants fed the two formulas compared with
the BFD group. Regarding body composition, length, head circumference and tricipital/subscapular
skinfolds were alike between groups. The INN formula was considered safe as weight gain and body
composition were within the normal limits, according to WHO standards. The BFD group exhibited
more liquid consistency in the stools compared to both formula groups. All groups showed similar
digestive tolerance and infant behavior. However, most adverse events were reported by the STD
formula group (291), followed by the INN formula (282) and the BFD groups (227). Nonetheless,
most of the adverse events (95.5%) were not considered to be related to the type of feeding There were
fewer respiratory, thoracic, and mediastinal disorders among BFD children. Additionally, infants
receiving the INN formula experienced significantly fewer general disorders and disturbances than
those receiving the STD formula Indeed, atopic dermatitis, bronchitis, and bronchiolitis were
significantly more prevalent among infants who were fed the STD formula compared to those fed BFD
formula or INN formula. To evaluate whether there are significant differences between formula
treatments, beyond growth parameters, it would seem necessary to examine more precise health
biomarkers including those based on omics sciences, such as metabolomics, proteomics and
metagenomics.

Clinical Trial Registration: The trial was registered with Clinicaltrial.gov (NCT05303077) on March
31, 2022, and lastly updated on April 7, 2022.

Keywords: Arachidonic acid (ARA); α-lactalbumin; *Bifidobacterium animalis* subsp. *lactis*, BPL1™;
body composition; docosahexaenoic acid (DHA); infant formula; postbiotics: protein; safety.

1.- Introduction

Exclusive breastfeeding is the gold standard for infant feeding because it not only promotes adequate
growth and development, excellent nutritional status, and appropriate psychological development, but
also, due to the special composition of breast milk in bioactive and immunogenic substances, it
effectively protects against numerous infectious diseases. In particular pneumonia and other respiratory
infections caused by bacteria and viruses, diarrhea and allergic processes. In addition, breastfeeding
promotes an optimal psycho-affective mother-child relationship and has a very low cost, practically nil
(Ip et al., 2009;Walker, 2010;Black et al., 2013;Victora et al., 2016;Ogbu et al., 2021). Indeed, WHO
and UNICEF recommend that children initiate breastfeeding within the first hour of birth and be
exclusively breastfed for the first 6 months of life – meaning no other foods or liquids are provided,
including water (World Health Organization, 2002;2022). However, from the age of 6 months, children
should begin eating safe and adequate complementary foods while continuing to breastfeed for up to 2
years and beyond (World Health Organization, 2022).

Breastfeeding protects against disease in both developing (Black et al., 2013) and developed countries
(Ip et al., 2009) and is beneficial not only for infants but also for mothers. Moreover, breastfeeding
may protect later in life against obesity and metabolic diseases. Indeed, breastfed children perform
better on intelligence tests, are less likely to be overweight or obese and less prone to diabetes later in
life (Rameez et al., 2019;World Health Organization, 2022). Also, women who breastfeed have a
reduced risk of breast and ovarian cancers (World Health Organization, 2022).

Despite worldwide efforts to promote breastfeeding, there are many social factors, especially premature
return to work after childbirth and, in some cases, maternal illness, which cause many mothers to
abandon breastfeeding prematurely (Balogun et al., 2015). In these cases, it is necessary to have infant
formula with an optimal nutritional composition to promote adequate growth and development, and
which are safe. In this regard, different entities such as ESPGHAN (Koletzko et al., 2005) and the AAP
have established various recommendations for the composition of infant formulas. In addition, various
governmental organizations, such as the FAO/WHO Codex Alimentarius Commission (CODEX
ALIMENTARIS, 2020), the European Union Commission (Commission Delegated Regulation (EU)
2016) and the US FDA (FOOD AND DRUG ADMINISTRATION, 2018) have established strict
compositional and control standards for infant formula foods to protect the health of consumers and
ensure fair practices in the food trade.

Continuous research on the composition of human milk and the biological effects of its components
(Christian et al., 2021) has led to the constant evolution of infant formula, especially during the last
five decades, incorporating new food ingredients to meet not only the nutritional needs of infants, but
also to contribute to the better development and functionality of their organs (Carver, 2003). Thus,
based on certain studies suggesting that a high protein intake in the early stages of life may be the cause
of obesity and increased risk of metabolic disease in later stages of life (Brands et al., 2014;Zheng et
al., 2018), the protein composition of infant formulas has been adjusted both in quality and quantity,
reducing the protein intake of infants to values very close to those obtained with breastfeeding. On the
other hand, the relatively high content of long-chain polyunsaturated fatty acids of both the n-6 and n-

3 series, especially arachidonic acid (AA, 20:4 n-6) and docosahexaenoic acid (DHA, 22:6 n-3) in
human milk and their proven effects on the cognitive development of infants, has led to the
incorporation of these fatty acids into infant formulas. In this regard, and despite the fact that EFSA
and the European Union Commission have established mandatory compositional recommendations
only for DHA content (EFSA Panel on Dietetic Products and Allergies, 2014;EU Commission, 2016),
numerous researchers have argued and established consensus documents on the need for infant
formulas to incorporate both AA and DHA in amounts comparable to the average composition of
human milk. In this regard, infant formula should provide DHA at levels of 0.3% to 0.5% by weight
of total fatty acids and with a minimum level of ARA equivalent to the DHA content (Koletzko et al.,
2020;Campoy et al., 2021).

During the last two decades, advances in the knowledge of the composition of the intestinal
microbiome of breast-fed infants and its beneficial effects on the host (Flaherman et al.,
2018;Gopalakrishna and Hand, 2020) have led to the incorporation of both prebiotics and probiotics in
infant formulas (Thomas et al., 2010;Braegger et al., 2011). In this regard, there is now some evidence
of the effects of prebiotics and probiotics incorporated into infant formulas in the prevention of acute
infectious diarrhea caused by different microorganisms, as well as in the treatment of antibiotic-
associated diarrhea and the prevention of allergy (Thomas et al., 2010;Braegger et al., 2011;Szajewska
et al., 2016;Adjibade et al., 2022). On the other hand, it is known that not only live probiotics but also
their fermentation products and death cells derived of inactivated probiotics, referred to by ISAPP as
postbiotics, can exert biological effects of interest on the intestinal microbiota (Salminen et al.,
2021;Vinderola et al., 2022). In this regard, it has been described that *Bifidobacterium animalis* subsp.
lactis CECT 8145 inactivated by heat (BPL1^{TM} HT) has been reported to exhibit several biological
effects of interest. Indeed, lipoteichoic acid from BPL1 BPL1^{TM} HT reduces fat deposition via the IGF-
1 pathway in mice (Balaguer et al., 2022) and has anti-obesity effects in obese Zucker rats (Carreras et
al., 2018). Moreover, daily consumption of the living strain BPL1^{TM} ameliorates several
anthropometric adiposity biomarkers in abdominally obese adults (Pedret et al., 2019). Likewise, an
infant formula supplemented with BPL1^{TM} HT reduced fat deposition in *C. elegans* and augmented
acetate and lactate in a fermented infant slurry (Silva et al., 2020).

The current infant formulas contain novel ingredients that mimic the composition and functionality of
human milk in part. Therefore, they should be tested clinically for tolerance, safety, and efficacy on
growth and development. Hence, in the present study we aimed to evaluate the effect of a novel starting
infant formula on weight gain in infants up to 6 and 12 months of age. This was compared to a standard
infant formula. Other body composition parameters (anthropometric data), as well as safety and
tolerability of both preparations, included digestive tolerance (flatulence, vomiting and regurgitation),
and stool (consistency and frequency), behavior (restlessness, colic, nocturnal awakenings), and
incidence of infections. Safety objectives included any adverse events resulting from the consumption
of the study formula. As a further exploratory objective, we compared weight gain up to 6 and 12
months and changes in the other secondary variables among the infants who received the modified
starter formula and the standard formula with a group of exclusively breastfed infants. The complete
design and methodology of this randomized, multicenter, double-blind, parallel, comparative clinical
trial of two infant formulas for infants with a reference of an exclusively breastfed infant group has
been previously registered with Clinicaltrial.gov (NCT05303077) on March 31, 2022, and lastly
updated on April 7, 2022, and published (Ruiz-Ojeda et al., 2022).

2.- Material and methods

2.1. Ethics

This clinical trial was carried out following the recommendations of the International Conference on Harmonization Tripartite, the ethical-legal principles established in the latest revision of the Declaration of Helsinki, as well as the current regional regulations that regulate pharmacovigilance and food safety. The study protocol and any material delivered to the subject, as well as any advertising material or compensation offered to the participating subjects. Prior to the study start, the Ethics Committee approves the study for Drug Research (ECDR). This approval was documented in a letter sent to each researcher specifying the date on which the ECDR met to give its approval. The present study was approved by the CEIm-R, the Committee for Technical Investigation in Regional Medicine in the Madrid Community (CEIm-R) dated 11/05/2018 under the name INNOVA2020 version 2.0. All personal data obtained in this study are confidential. They were treated in accordance with the Spanish Organic Law 3/2018, of December 5, on the Protection of Personal Data and guarantee of digital rights. The researcher or the institution allowed direct access to the data or source documents for monitoring, auditing, and review by the ECDR. This also allowed inspection of the trial by the health authorities.

2.2. Trial design

The INNOVA study was designed as a randomized, multi-center, double-blind, parallel, and comparative clinical trial of the equivalence of two starting infant formulas for infants. Furthermore, a third un-blinded group of breastfed infants was used as a further reference group for exploratory analysis. Blinding for both investigator and participant remained assured as both infant formulas were labeled the same. It is not mandatory to carry out specific clinical tests to demonstrate the nutritional and healthy properties of infant formulas as per the current EU legislation (EC Regulation No. 1924/2006) (Ruiz-Ojeda et al., 2022).

Parents were informed by pediatricians involved in the study of the possibility of participating in it at a meeting at 15 days of infant age. After accepting to participate, they came to the health center for the baseline visit a week later (visit at 21 days of age). The pediatrician requested, at the meeting at 15 days of life, that parents provide at the next visit relevant information from the maternal history that was required for the study and that was not available in the pediatric history. The visit that took place within the scheduled time was considered valid with a margin of $\pm$ 3 days in the visit at 21 days of age, $\pm$ 1 week in the visit at 2 months of age, and $\pm$ 2 weeks in visits at 4, 6 and 12 months of age. The inclusion criteria were healthy children of both sexes; term children (between 37 and 42 weeks of gestation), birth weight between 2500-4500 g, single delivery, and mothers with a body mass index, before pregnancy, between 19 and 30 kg/m^2. The exclusion criteria were, body weight less than the 5th percentile for that gestational age, allergy to cow's milk proteins and/or lactose, history of antibiotic use during the 7 days before inclusion, congenital disease or malformation that can affect growth, diagnosis of disease or metabolic disorders, significant prenatal and/or severe postnatal disease before enrollment, minor parents (younger than 18 years old), newborn of a diabetic mother, newborn of a mother with drug dependence during pregnancy, newborn whose parents/caregivers cannot comply with procedures of the study, and infants participating or have participated in another clinical trial since their birth. Participants had the right to withdraw from the study at any time and for any reason, without giving explanations or suffering any penalty for it. Likewise, the investigator could withdraw study participants if they did not comply with the study procedures. This is for any reason that, in the investigator's opinion, may pose the infants at risk or makes it necessary to suspend breastfeeding. The following treatments were forbidden in the trial: antibiotics during the 7 days prior to inclusion,

antibiotics for 10 days during the trial, any treatment, food or product that could interfere with the trial
at any time, and breastfeeding which was different from that of the group assigned group in the trial.

The sample size of the trial is 210 children (70/group), based on the main outcome of weight gain,
which is the main variable chosen according to the guidelines "Guidelines from the American Academy
of Pediatrics Task Force on Clinical Testing of Infant Formulas" (Task force on clinical testing of
infant formulas committee on nutrition. American Academy of Pediatrics Committee on Nutrition et
al., 1988). The infants were selected by Primary Care pediatricians in competitive recruitment. The
study was carried out in 21 centers, all located in Spain, of which 17 recruited at least one subject. In
total, 217 subjects signed the informed consent (IC) and 145 were randomized to receive one of the
two infant formulas. Of these 145, 3 were randomization failures and 2 were screening failures, thus
140 infants who met all the inclusion criteria and no exclusion criteria were included in the study, and
70 were unblinded within infants exclusively breastfed. A total of 185 subjects completed all study
visits, of which there were 25 dropouts, 12 in the breastfeeding group, 8 in the formula 1 group, and 5
in the standard formula group. The trial was registered with clinicaltrial.gov website (NCT05303077,
https://clinicaltrials.gov/ct2/show/NCT05303077) on March 31, 2022, and lastly updated on April 7,
2022. Figure 1 summarizes the disposition of the subjects in the study.

2.3 Formula characteristics

•Group 1 (Infant formula 1): Nutribén® Innova 1

•Group 2 (Infant formula 2): Nutribén® Standard

•Group 3: Breastfeeding (External control exploratory analysis)

Infants were recruited from Primary Care Pediatrics clinics by the pediatricians participating in the
trial. Pediatricians informed and invited parents of 15-day-old infants who visited their offices regularly
(for regular medical check-ups) to be involved in the trial. Infants that were not a candidate for
breastfeeding (for different reasons) were proposed to participate in the formula-feeding groups. To
keep the three arms of the trial balanced, one candidate breastfeeding subject was recruited at each
center for every two infants supplemented with infant formula. The selection of the children of the
breastfeeding group was made among those infants who met the inclusion and exclusion criteria of the
study and fit the categories of sex, body mass index of the mother before pregnancy (<25, >25kg/m2),
and birth weight (<3500 g, >3500 g) of the last infant in the formula-fed group included in the center.

The experimental product object of this trial (Formula 1 or Nutribén® Innova 1, INN formula) and the
Nutribén® Standard formula (STD formula) comply with the recommendations of the ESPGHAN
(European Society of Pediatric Gastroenterology, Hepatology and Nutrition) and with Regulation
609/2013 of the European Parliament and of the Council regarding foods intended for children, infants
and young children, foods for special medical purposes and complete diet substitutes for weight control
and repealing Council Directives 92/51, Directives 96/8/EC, 1999/21/CE, 2006/125/CE and
2006/141/CE of the Commission, Directive 2009/38/CE of the European Parliament and of the Council
and Regulations 41/2009 and 953/2009 of the Commission. More detailed information on the
composition of each of the products can be found in additional information (Supplementary Table S1).
Infant formulas are given ad libitum orally. The two trial formulations were administered following
the preparation instructions in the manufacturer's package insert.

2.4 Measurements and evaluations

2.4.1 Anthropometric measures

Weight, length, and head circumference measurements were taken at all study visits (visit 1, 21 days,
visit 2, 2 months, visit 3, 4 months, visit 4, 6 months, and visit 5, 12 months). From the visit scheduled
for the fourth month of life, the mean arm circumference, the triceps skinfold, and the subscapular
skinfold were added to the previous measurements. All these measurements were done in duplicate.
Using as valid data the mean between the two. Each center had all the necessary materials to carry out
these measurements. They needed to always use the same material with all subjects and, of course, the
material should be calibrated.

2.4.2 Characteristics of the feces and digestive tolerance

We evaluated consistency and the number of stools/day) at times 21 days, 2, 4, 6 and 12 months of age
were evaluated as well as, flatulence, vomiting and regurgitation at times 21 days, 2, 4, 6 and 12 months
of age.

2.4.3 Behavior and global evaluation of the parents

Global evaluation of the parents. Infant's behavior. Restlessness, colic, and night awakenings were
evaluated during 21 days, 2, 4, 6 and 12 months of age.

2.4.4 Morbidity, safety and tolerability of the products

Variables were evaluated within 1-year morbidity and in the course of 1 year, respectively. All adverse
events have been coded according to MedDRA dictionary version 21.0 (MedDRA, 2018).

2.5 Statistical methods

The main objective of the study was to evaluate whether the weight gain was equivalent between
treatment groups receiving formula 1 and 2, and it has been decided that the sample size of the trial is
210 children (70/group). Previous studies carried out on children fed from 0 to 6 months with different
formulations of infant formula have shown a mean weight gain of around 20-25 g/day with a standard
deviation between 5 and 6 g/day. In most of these studies, a difference in mean weight gain of 3 g/day
was considered clinically relevant. Thus, the main objective was resolved by using a t-test for
independent samples. Considering a power of 80%, a significance level of 5%, an equivalence limit of
3 g/day, and a common standard deviation of 5.5 g/day, we needed to recruit at least 59 children in
each of the groups. Based on an estimated dropout rate of 20%, it was necessary to include 70 children
in each of the groups, which means 140 infants. A third group of the same size (70 children) was
included for the secondary comparisons between the bottle-fed and breastfed groups, maintaining the
same significance and power in this secondary comparison as in the main comparison. Categorical
variables are described as frequencies or percentages. Continuous variables are reported as mean and
standard deviation. Between-group differences in measures of growth and body composition are
analyzed using analysis of variance, including analysis of covariance and general models of analysis
of variance for repeated measures when required. The Chi-square test is applied to compare discrete

variables between groups. The Bonferroni correction is used when comparisons are made between
more than two groups. The alpha level of significance is set at 0.05. All evaluable infants have been
included in the statistical analysis, considering "evaluable" all those who have the main measurement
variable. Both, intention to treat and protocol-based statistical analyses are performed.

3.- Results

In **table 1** shows demographic and descriptive information. Here, gestational age, birth weight,
childbirth delivery, assisted reproductive technology, and the mother's medical background were
included, though no significant variables were shown. During visit 1 (21 days), only daily depositions
per day were significantly higher for the BFD group in comparison with formula groups.

The parents or legal guardians returned to the center all the leftover containers (empty containers and
containers with products) in order to record the amount of product dispensed and the amount of infant
formula used up to the time of the visit; the corresponding weighing was performed and the percentage
of product ingested by the participants was determined. Finally, the grams of formulation consumed
by each infant, measured by weighing the leftover formulations or as indicated in the parents' diary
corresponding to the periods between visits 1-2, 2-3 and 3-4, were available. The participants of this
study included in the formula-feeding groups were considered compliant if they took at least 80% of
the formula during the first six months while in the breastfeeding group it was considered a valid
external control if more than 80% of the feedings were breastfeeding. All infants included in the BFD
group, except one, consumed more than 80% of the formula during the first six months.

A repeated measures analysis of variance (ANOVA) was performed for grams consumed per day
according to weighing, and significant differences were observed for visit, sex and infant birth weight,
but not in relation to the formula used (data not presented). The ANOVA for grams consumed per day
according to parents' diaries also showed significant differences as a function of visit, sex and infant
birth weight, but not as a function of the formulation used (data not presented).

Table 1. Baseline demographics of the infants in the study

	BFD	STD	INN	P-value
N	70	70	70	
Gender (% of women)	28 (40.0)	29 (41.4)	33 (47.1)	0.738
Gestational age (weeks)	39.44 (1.1)	39.20 (1.1)	39.34 (0.9)	0.389
Birth weight (g)	3359.20 (403.9)	3300.87 (462.9)	3363.30 (408.7)	0.626
Birth weight >3500 g (%)	22 (31.4)	22 (31.4)	27 (38.6)	0.613
Childbirth delivery n, (%)				0.579
Cesarean section	13 (18.6)	17 (24.3)	20 (28.6)	
Distocyc	8 (11.4)	6 (8.6)	9 (12.9)	
Normal childbirth	49 (70.0)	47 (67.1)	41 (58.6)	
Assisted reproductive technology n, (%)	4 (5.7)	6 (8.6)	3 (4.3)	0.679
Assisted reproductive technology type (%)				0.066
In vitro fertilization	1 (25.0)	6 (100.0)	2 (66.7)	
Artificial insemination	2 (50.0)	0 (0.0)	1 (33.3)	
Egg donation	1 (25.0)	0 (0.0)	0 (0.0)	
Maternal BMI (kg/m^2), (x, SD)	23.72 (3.2)	23.92 (3.3)	23.78 (3.0)	0.967
BMI mother>25 n, (%)	22 (31.4)	22 (31.4)	24 (34.3)	0.85
Single pregnancy n, (%)	70 (100.0)	70 (100.0)	70 (100.0)	NS
Mother's medical background n, (%)				0.849
Allergy	0 (0.0)	0 (0.0)	2 (2.9)	
Hypothyroidism	7 (10.0)	5 (7.1)	4 (5.7)	
Arterial hypertension	0 (0.0)	2 (2.9)	1 (1.4)	
No	58 (82.9)	55 (78.6)	55 (78.6)	
Others	5 (7.1)	8 (11.4)	8 (11.4)	
Visit 1, (21 days)	**BFD**	**STD**	**INN**	**P-value**
Depositions per day	5.2 (3.2)	2.5 (2.0)	2.3 (1.4)	<0.001*
Weight	3921.8 (475.5)	3805.0 (507.5)	3916.6 (453.9)	0.268
Length	53.1 (1.9)	52.6 (2.2)	52.8 (1.7)	0.287
Head circumference	36.6 (1.0)	36.2 (1.3)	36.5 (1.2)	0.214

337   Data are expressed as mean and standard deviation, and frequency or percentage. BMI, body mass index; NS, non-significant

Table 2. Weight and differential daily weight gain in the entire study

Differential daily weight gain per day (g)						
Groups	**BFD**	**STD**	**INN**		**P-value**	
Visits	**(N=58)**	**(N=65)**	**(N=62)**	**STD vs. BFD**	**INN vs. BFD**	**STD vs. INN**
Visit 4 vs Visit 1	22.0 ± 4.6	24.24 ± 5.06	24.60 ± 5.29	0.01	0.004	0.693
Visit 5 vs visit 1	16.01 ± 2.66	17.41 ± 3.25	17.00 ± 2.95	0.011	0.057	0.457
Weight (g)						
Groups	**BFD**	**STD**	**INN**		**P-value**	
Visits	**(N=58)**	**(N=65)**	**(N=62)**	**Formula**	**Visit**	**Formula x visit**
Visit 1, 21 days	3951.3 ± 498.0	3805.8 ± 509.6	3916.9 ± 468.7			
Visit 2, 2 months	5285.1 ± 564.9	5193.7 ± 684.0	5236.6 ± 623.2			
Visit 3, 4 months	6558.6 ± 697.1	6733.0 ± 937.7	6843.1 ± 855.1	0.081	0.848	0.011
Visit 4, 6 months	7471.1 ± 846.3	7718.7 ± 1132.8	7903.1 ± 1063.5			
Visit 5, 12 months	9505.2 ± 985.6	9869.7 ± 1382.1	9797.6 ± 1234.4			

Data are expressed as mean and standard deviation

The primary variable (weight gain) consisted of the difference in infant weight (in g/day) between the initial recruitment visit and the 6-month visit, divided by the number of days between the two visits. This analysis was performed on the 187 infants who completed until visit 4 (6 months). The difference between visit 1 and visit 4 was calculated in days of 187 children individually (**Table 2**). When analyzing the mean difference in weight gain between the groups of children treated with the STD and INN formulations (**Table 2**), there was no statistically significant difference in weight gain between the two formulations. On the other hand, an ANOVA of the weight difference between visits 1 and 4 was performed for the STD and INN formulations controlling for the factors, gender, maternal body mass index (BMI) and birth weight. There were significant differences in weight difference between visits 1 and 4 as a function of gender and infant birth weight, but not as a function of formulation or mother's BMI (**Table 2**). The grams consumed per day were also related to the difference in weight between visits 1 and 4. Based on the weighing of leftover grams of the dispensed formulation, a multivariate analysis of variance (MANOVA) of the difference in weight of the children between visits 1 and 4 was performed as a function of formulation consumed (STD, INN), gender (male, female), maternal BMI (<25, >25), birth weight (<3500, >3500) and grams ingested per day. A moderate positive correlation (r=0.535) was observed between mean grams ingested per day (measured by weighing leftover formulations) and weight gain between visits 1 and 4 of the infants. This correlation changed significantly by gender (males achieved larger weight differences for the same daily grams of formulation consumed) and by birth weight (infants with birth weights > 3500 achieved larger weight differences for the same daily grams of formulation consumed) but not as a function of maternal BMI or formulation used.

This same MANOVA as a function of grams ingested daily according to parental diary also showed a positive correlation (r=0.626) between mean grams ingested per day (obtained from parental diary entries) and weight gain between visits 1 and 4 of the infants. This correlation changed significantly by gender (boys achieved larger weight differences for the same daily grams of formulation consumed)

and by birth weight (children with birth weights > 3500 achieved larger weight differences, especially
those who consumed more daily grams of formulation) but not as a function of maternal BMI or
formulation used.

Secondarily and foreseen in the study protocol, the weight gain of the infants who received each of the
formulations studied was compared with the BFD group. The results of this analysis are shown in
Table 2, where it can be seen that BFD infants had a significantly lower weight gain at 6 months of
age than that shown by infants fed with either of the two formulations evaluated (STD and INN).

The same analysis was performed for the variable weight gain at 12 months of study. **Table 2** shows
the number of children in each of the 3 groups studied with weight values recorded at visit 1 (21 days
of age) and visit 5 (12 months ± 2 weeks). A comparison of the means of weight gain from the different
formulations (STD vs. INN, STD vs. BFD and, INN vs. BFD, **Table 2**) revealed that at 6 months there
is no significant difference in weight gain (measured in g/day) as well as at 12 months between the
STD and INN formulations. Moreover, the secondary comparisons of each of the formulations with
breastfeeding show an equalization between formulations with the INN formulation not being
significantly different from breastfeeding. On the contrary, the total weight gain of the STD
formulation group remained significantly higher than the BFD group at 12 months. ANOVA (data not
presented) shows significant differences for visit ($p<0.001$) and for the interaction between formulation
and visit ($p=0.004$), but not for formulation exclusively ($p=0.381$). The largest effect size was
associated with the visit factor (0.8477).

Table 3. Length and head circumference in the entire study

Visits	Length (cm)		
	BFD (N=58)	**STD** (N=65)	**INN** (N=62)
Visit 1	53.15 ± 2.08	52.49 ± 2.24	52.87 ± 1.78
Visit 2	57.89 ± 2.42	57.47 ± 2.33	57.95 ± 2.02
Visit 3	63.16 ± 2.42	63.24 ± 3.67	63.50 ± 2.16
Visit 4	66.68 ± 2.64	67.01 ± 3.26	67.15 ± 2.14
Visit 5	75.44 ± 2.90	75.82 ± 3.08	75.96 ± 2.54
Visits	Head circumference (cm)		
	BFD (N=58)	**STD** (N=65)	**INN** (N=62)
Visit 1	36.66 ± 1.02	36.22 ± 1.34	36.51 ± 1.25
Visit 2	36.09 ± 1.17	38.87 ± 1.36	39.11 ± 1.63
Visit 3	41.56 ± 1.12	41.79 ± 3.73	41.64 ± 1.39
Visit 4	43.19 ± 1.22	43.18 ± 1.37	43.41 ± 1.45
Visit 5	46.40 ± 1.18	46.25 ± 1.53	46.29 ± 1.50

395 Data are expressed as mean and standard deviation

396 No significant differences were observed in length and head circumference, as well as, tricipital and
397 subscapular skinfolds and mean upper arm circumference (**Tables 3** and **4**).

405
406
407
408
409 **Table 4.** Tricipital and subscapular skinfolds and mean upper arm circumference in visits 3, 4, and 5.

		Tricipital skinfold (mm)		
		BFD	**STD**	**INN**
		(N=58)	**(N=65)**	**(N=62)**
	Visit 3	12.32 ± 2.26	12.66 ± 2.67	12.78 ± 3.00
	Visit 4	12.35 ± 2.23	12.60 ± 2.65	12.90 ± 2.99
	Visit 5	12.34 ± 2.23	12.63 ± 2.65	12.84 ± 2.99
		Subscapular skinfold (mm)		
		BFD	STD	INN
		(N=58)	(N=65)	(N=62)
	Visit 3	9.92 ± 2.69	9.83 ± 2.72	10.25 ± 2.73
	Visit 4	9.90 ± 2.49	9.94 ± 2.72	10.36 ± 2.73
	Visit 5	9.91 ± 2.58	9.89 ± 2.73	10.30 ± 2.72
		Mean upper arm circumference (cm)		
		BFD	**STD**	**INN**
		(N=58)	**(N=65)**	**(N=62)**
	Visit 3	13.79 ± 1.30	13.89 ± 1.67	14.15 ± 1.21
	Visit 4	14.41 ± 1.24	14.72 ± 1.46	14.98 ± 1.88
	Visit 5	15.34 ± 1.26	15.29 ± 1.68	15.94 ± 1.39

410 Data are expressed as mean and standard deviation

411 **Table 5.** Body mass index, body fat percentage, and lean mass.

	Body mass index (kg/m^2)			**P-value**		
Visits	**BFD** **(N=58)**	**STD** **(N=65)**	**INN** **(N=62)**	**Formula**	**Visit**	**Formula x visit**
Visit 1	13.94 ± 1.11	13.75 ± 1.04	13.97 ± 1.07			
Visit 2	15.74 ± 1.08	15.67 ± 1.30	15.56 ± 1.28			
Visit 3	16.42 ± 1.22	16.97 ± 3.61	16.94 ± 1.59	0.487	<0.001	<0.001
Visit 4	16.78 ± 1.30	17.15 ± 1.83	17.49 ± 1.81			
Visit 5	16.69 ± 1.28	17.11 ± 1.64	16.94 ± 1.54			
	Body fat percentage			**P-value**		
Visits	**BFD** **(N=58)**	**STD** **(N=65)**	**INN** **(N=62)**	**Formula**	**Visit**	**Formula x visit**
Visit 3	19.35 ± 3.53	19.60 ± 3.39	20.37 ± 3.67			
Visit 4	20.36 ± 3.53	20.30 ± 3.73	21.29 ± 3.93	0.249	0.005	0.958
Visit 5	20.84 ± 3.64	21.02 ± 3.82	21.61 ± 4.01			
	Lean mass (g)			**P-value**		
Visits	**BFD** **(N=58)**	**STD** **(N=65)**	**INN** **(N=62)**	**Formula**	**Visit**	**Formula x visit**
Visit 3	5284 ± 559	5403 ± 709	5436 ± 615			
Visit 4	5942 ± 654	6135 ± 823	6207 ± 782	0.215	<0.001	0.054
Visit 5	7509 ± 703	7805 ± 1023	7670 ± 967			

Data are expressed as mean and standard deviation

In the case of BMI, the ANOVA (**Table 5**) shows significant differences for visit (p<0.001) and for
the interaction between formulation and visit (p<0.001), but not for formulation (p=0.487). The largest
effect size was associated with the visit factor (0.4230, data not provided). In addition, we have reported
that it was from the third visit onwards that the mean BMI was higher in the STD and INN formulations
compared to the BFD group; hence, the interaction effect appears as significant (**Table 5**). For the body
fat percentage, the ANOVA (**Table 5**) shows significant differences for visit (p=0.005), but not for the
interaction between formulation and visit (p=0.958) and for formulation (p=0.249). The largest effect
size is associated with the visit factor (0.0236, data not shown). Finally for the lean mass, the ANOVA
(**Table 5**) shows significant differences for visit (p<0.001), but not for the interaction between
formulation and visit (p=0.054) and for formulation (p=0.215). The largest effect size is associated
with the visit factor (0.6093, data not provided).

In the case of BMI percentiles, the ANOVA (**Table S2**) reveals significant differences for visit
(p=0.009) and the interaction between formulation and visit (p=0.006), but not for formulation
(p=0.504). The largest effect size is associated with the visit factor (0. 0222, data not provided). In the
ANOVA, there were significant differences in the height percentiles for visit (p=0.011), for the
interaction between formulation and visit (p<0.001), but not for formulation (p=0.433, **Table S2**). The
largest effect size is associated with the visit factor (0.0154, data not shown). Finally, in the weight
percentiles, the ANOVA (**Table S2**) shows significant differences for visit (p<0.001) and for the
interaction between formulation and visit (p<0.001), but not for formulation (p=0.368). The largest
effect size is associated with the visit factor (0.0228, data not provided).

The time course of the study shows a difference between breastfed infants presenting stools of a more
liquid consistency (**Table S3**), although these differences ceased to be significant at visit 5 (see **table
S3**). Likewise, the daily number of stools was higher in breastfed infants at visits 1, 2 and 3, but these
differences ceased to be significant at visits 4 and 5 (**Table 6**).

Table 6. The daily number of stools.

Number of daily depositions	Visit 1	Visit 2	Visit 3	Visit 4	Visit 5
	BFD				
Mean (SD)	5.2 (3.2)	3.1 (2.3)	2.3 (1.5)	2.0 (1.4)	1.8 (1.0)
Median [Min, Max]	5 [3, 8]	3 [1, 4]	2 [1, 3]	2 [1, 2]	2 [1, 2]
	STD				
Mean (SD)	2.5 (2.0)	1.5 (0.7)	1.3 (0.6)	1.5 (1.0)	1.9 (0.9)
Median [Min, Max]	2 [1, 4]	1 [1, 2]	1 [1, 2]	1 [1, 2]	2 [1, 2]
	INN				
Mean (SD)	2.3 (1.4)	1.6 (0.8)	1.6 (0.9)	1.6 (0.9)	1.9 (0.8)
Median [Min, Max]	2 [1, 3]	1 [1, 2]	1 [1, 2]	1 [1, 2]	2 [1, 2]

438 Data are expressed as mean and maximum and minimum

439 **Table 7** shows the tabulation of the different categories of digestive tolerance between each two visits.
440 An increase in the percentage of children with high tolerance is seen throughout the study without
441 significant differences between the different formulations and compared with the BFD group.

442
443
444

Table 7. Digestive tolerance

Digestive tolerance	BFD (N=65)	STD (N=66)	INN (N=64)
Period between visits 1 and 2			
Adequate	33 (50.8%)	38 (57.6%)	29 (45.3%)
Constipation	0 (0%)	0 (0%)	1 (1.6%)
Flatulence	11 (16.9%)	8 (12.1%)	12 (18.8%)
Vomiting	1 (1.5%)	1 (1.5%)	0 (0%)
Others			
Colic	0 (0%)	0 (0%)	2 (3.1%)
Irritability	1 (1.5%)	0 (0%)	0 (0%)
Regurgitation	19 (29.2%)	19 (28.8%)	20 (31.3%)
Period between visits 2 and 3			
Digestive tolerance	BFD (N=65)	STD (N=66)	INN (N=64)
Adequate	38 (62.3%)	43 (65.2%)	33 (52.4%)
Constipation	0 (0%)	0 (0%)	1 (1.6%)
Flatulence	2 (3.3%)	2 (3.0%)	7 (11.1%)
Vomiting	0 (0%)	2 (3.0%)	0 (0%)
Others			
Irritability	2 (3.3%)	0 (0%)	0 (0%)
Regurgitation	19 (31.2%)	19 (28.8%)	22 (34.9%)
Period between visits 3 and 4			
Digestive tolerance	BFD (N=65)	STD (N=66)	INN (N=64)
Adequate	37 (63.8%)	52 (78.8%)	44 (69.8%)
Constipation	0 (0%)	0 (0%)	0 (0%)
Flatulence	6 (10.3%)	2 (3.0%)	4 (6.4%)
Vomiting	0 (0%)	0 (0%)	0 (0%)
Others			
Diarrhea	0 (0%)	0 (0%)	1 (1.6%)
Abdominal pain	0 (0%)	1 (1.5%)	0 (0%)
Period between visits 4 and 5			
Digestive tolerance	BFD (N=65)	STD (N=66)	INN (N=64)
Adequate	56 (96.6%)	64 (98.5%)	59 (95.2%)
Constipation	0 (0%)	0 (0%)	0 (0%)
Flatulence	1 (1.7%)	0 (0%)	1 (1.6%)
Vomiting	0 (0%)	0 (0%)	0 (0%)
Others			
Regurgitation	1 (1.7%)	1 (1.5%)	1 (1.6%)

Data are expressed as counts and percentages

The infant's behavior was recoded as altered mood or pleasant mood according to the guardians or parents. **Table S4** shows how the percentage of infants with altered behavior decreased throughout the study. No significant differences were observed among the three ways of feeding.

The study found no differences in tolerability between the different groups (**Table S5**). According to the safety of the different formulations, the majority of the adverse events (n=754) were mild - Grade 1 (94.3%), 13 were moderate-Grade 2 (1.6% of the total) and none were severe-Grade 3. The intensity was not recorded for 33 of the events (4.1%) (**Table 12**). There were no differences between the different groups concerning the intensity of the events. For example, there were 93.0% of mild events in the BFD group, 91.8% in the INN group, and 97.6% in the STD group.

Table 8. Adverse events across the study

Total adverse events	BFD (N=70)	STD (N=70)	INN (N=70)
Subjects with at least one adverse event (%)	62 (88.6%)	57 (81.4%)	61 (87.1%)
Total number	227	291	282
Mild - Grade 1	211	284	259
Moderate - Grade 2	3	3	7
Severe - Grade 3	0	0	0
Potentially fatal - Grade 4	0	0	0
Lethal - Grade 5	0	0	0
Unknown	13	4	16
Adverse events related to feeding	**BFD (N=70)**	**STD (N=70)**	**INN (N=70)**
Subjects with at least one adverse event (%)	1 (1.4%)	1 (1.4%)	1 (1.4%)
Total number	1	2	2
Mild - Grade 1	1	2	2
Moderate -Grade 2	0	0	0
Severe - Grade 3	0	0	0
Potentially fatal - Grade 4	0	0	0
Lethal - Grade 5	0	0	0
Unknown	0	0	0

Data are expressed as counts and percentages

Most of the adverse events (95.5%) were not considered to be related to the type of feeding (**Table 8**), but only 5 were considered possibly related (**Table 8**). All of them were mild, with 1 growth failure, within the BFD group that led to the introduction of artificial breastfeeding together with breastfeeding, two events, neonatal constipation, and abdominal pain, recorded by one infant within the INN group, led to the change of formula and the abandonment of the study and two (infantile colic and infant reflux) recorded by one infant within the STD group that led to the change of formula and the abandonment of the study (**Table 8**). . For adverse events that occur with a frequency greater than 1%, BFD infants exhibited the lowest incidence and infants fed INN formula experienced significantly fewer general disorders and disturbances compared with the STD group. Indeed, the infants who were

fed STD formula had a significantly higher incidence of atopic dermatitis, bronchitis and bronchiolitis events than the infants who were fed BFD or INN formula (**Table 9**).

Table 9. Adverse events that occur with a frequency greater than 1%.

MedDRA dictionary version 21.0 (MedDRA, 2018)	BFD (N=70)		STD (N=70)		INN (N=70)	
	Cases	%	Cases	%	Cases	%
Cold	42	18.50%	47	16.15%	38	13.48%
Pyrexia	16	7.05%	24	8.25%	11	3.90%
Bronchiolitis*	8	3.52%	19	6.53%	11	3.90%
Upper respiratory tract infection	11	4.85%	11	3.78%	15	5.32%
Infantile colic	14	6.17%	9	3.09%	10	3.55%
Conjunctivitis	5	2.20%	11	3.78%	15	5.32%
Bronchitis*	5	2.20%	15	5.15%	6	2.13%
Neonatal constipation	6	2.64%	10	3.44%	9	3.19%
Acute otitis media	4	1.76%	6	2.06%	13	4.61%
Rhinorrhea	9	3.96%	5	1.72%	6	2.13%
Gastroenteritis	4	1.76%	8	2.75%	8	2.84%
Cough	9	3.96%	7	2.41%	5	1.77%
Vaccination complication	1	0.44%	10	3.44%	7	2.48%
Laryngitis	1	0.44%	9	3.09%	7	2.48%
Atopic dermatitis*	1	0.44%	11	3.78%	2	0.71%
Seborrheic dermatitis	2	0.88%	4	1.37%	5	1.77%
Neonatal diarrhea	2	0.88%	3	1.03%	5	1.77%
Oral candidiasis	4	1.76%	3	1.03%	2	0.71%
Nasopharyngitis	1	0.44%	2	0.69%	6	2.13%
Infantile eczema	1	0.44%	5	1.72%	2	0.71%
Diaper dermatitis	2	0.88%	2	0.69%	4	1.42%
Rash	3	1.32%	2	0.69%	2	0.71%
Neonatal disorder	2	0.88%	1	0.34%	4	1.42%
Upper respiratory tract infection	2	0.88%	1	0.34%	3	1.06%
Wheezing	2	0.88%	3	1.03%	1	0.35%
Infant reflux	1	0.44%	2	0.69%	3	1.06%
Otitis media	4	1.76%	1	0.34%	1	0.35%
Gastroesophageal reflux disease	4	1.76%	0	0.00%	1	0.35%
Heart murmur	4	1.76%	1	0.34%	0	0.00%
Diarrhea	1	0.44%	0	0.00%	4	1.42%
Dermatitis	1	0.44%	3	1.03%	0	0.00%
Traumatic head injury	0	0.00%	1	0.34%	4	1.42%
Abdominal pain	0	0.00%	1	0.34%	3	1.06%
Bronchial hyperreactivity	0	0.00%	3	1.03%	0	0.00%
Decreased appetite	0	0.00%	3	1.03%	0	0.00%
Pharyngotonsillitis	0	0.00%	1	0.34%	3	1.06%
Umbilical hernia	0	0.00%	1	0.34%	3	1.06%
Viral rash	0	0.00%	1	0.34%	3	1.06%
Traumatic injury to the mouth	1	0.44%	0	0.00%	3	1.06%
Total	173		246		225	

Data are expressed as counts and percentages, *P<0.05 BFD and INN vs. STD group.

4.- Discussion

The present randomized, double-blind, placebo-controlled clinical trial has been designed to determine whether a novel starting infant formula with reduced protein content and lower casein to whey protein ratio of approximately 70/30 by increasing the content of α-lactalbumin, might be beneficial to the health of infants. Furthermore, this product contains higher levels of DHA and ARA, as well as a post-biotic thermally inactivated (BPL1^{TM} HT), compared with standard infant formula. An exclusively breastfed population was followed-up as a reference. At 6 and 12 months, infants receiving either INN or STD formula gained more weight than the BFD group, while no difference was observed between STD and INN formulas. BMI was also higher in infants fed the two formulas than in those fed BFD. In terms of body composition, length, head circumference, and tricipital/subscapular skinfolds were similar between the groups. It is important to note that the INN formula was considered safe based on weight gain and body composition, which were within the normal limits, according to WHO standards. Compared to both formulas, BDF produced stools that were more liquid in consistency. Throughout the study period, all groups exhibited similar digestive tolerance and infant behavior. In terms of the total number of adverse events reported, the STD formula has the highest number (291), followed by the INN formula (282) and finally, the BFD group (227). However, the majority of them were not related to type of feeding. Nonetheless, infants fed either BFD or the INN formula exhibited significantly lower episodes of atopic dermatitis, bronchitis and bronchiolitis events than those fed the STD formula.

Breastfeeding is one of the most effective methods for ensuring a child's health and well-being (Dieterich et al., 2013). Despite this, nearly two out of three infants are not exclusively breastfed for the recommended six months - a rate that has not improved in the past two decades (Jama et al., 2020). It is recommended that infants consume breast milk as their primary source of nutrition. It is a safe, clean product containing antibodies that help protect children against a wide range of common childhood diseases (Rollins et al., 2016; Victora et al., 2016). During the first few months of life, breastmilk provides the infant with all the nutrients and energy required, and for the remainder of the first year, breastmilk continues to meet about half of the child's nutritional needs, and for up to one-third of the child's nutritional requirements in the second year (World Health Organization, 2022)

In general, the low rate of exclusive breastfeeding can be attributed to a variety of factors, including maternal smoking, educational level, and the need to return to work (Scott et al., 2006; Libuda et al., 2014; Papadopoulos et al., 2022). In the current situation, three out of five infants are not breastfed in the first hour of their lives (World Health Organization, 2022). When breastfeeding is not possible, unsuitable, or inadequate, an interruption or cessation is warranted. Around the world, only 38% of infants are exclusively breastfed (Martin et al., 2016). Only 75% of American infants have been breastfeeding from birth. By the age of three months, however, 67%, or 2.7 million, of them are consuming some amount of infant formula (CODEX ALIMENTARIS, 2020). According to the U.S. Census Bureau, only 13% of first-time mothers who meet the recommendation to exclusively breastfeed for six months meet the recommendation for "any breastfeeding" after six months (Eidelman et al., 2012). Although infant formulas have been partially formulated to mimic the nutritional profile of human breast milk for normal infant development and growth, there is still a need for further research to improve these formulas (Kent, 2015).

It is pertinent to note that, in addition to exposure to metabolic and endocrine factors during pregnancy (Monasta et al., 2011), protein intake in formula-fed infants during their first year of life may have a significant impact on growth later in life and the risk of obesity and metabolic disorders in adulthood (Koletzko et al., 2009;Zheng et al., 2018). The protein content of infant formula is usually greater than

that of human milk to provide all essential amino acids in adequate quantities. The research indicates
that infants fed a formula containing more protein gain more weight during the first year of life and are
heavier at 2 years of age than infants consuming a formula containing less protein (Koletzko et al.,
2009), which reduces the risk of obesity at school age (at age 6). Both formulas gained more weight
than the BFD group at 6 months as measured by differential daily weight gain per day (g), while no
difference was observed between STD and INN formulas. After 12 months, the STD group was
significantly higher than BFD and INN groups. INN formula contains 8% less protein per 100 kcal
than the STD. In the first six to eight weeks of life, there is almost no difference between breast milk
and formula-fed infants in terms of growth (gain in weight and length). Formula-fed infants gain weight
and length more rapidly than breast-fed infants from about two months of age to the end of their first
year of life (Ziegler, 2006). The results of a recent review suggest that the difference in weight gain
between formula-fed and breastfed infants is relatively small, comparable, and significantly less than
the nutritionally significant differences used in determining sample size (Wallingford and Barber,
2019). Compared with exclusively breastfed infants, formula-fed infants gained weight more rapidly
and out of proportion to linear growth. Lean mass accretion was greater than fat mass accretion in this
study.

The intake of infant formula does not appear to be associated with an increased risk of obesity later in
life (Bell et al., 2017), however, controversy surrounds this issue at present. New research from First
Steps Nutrition Trust identifies the key steps required to protect children from overweight and obesity
during the first 1,000 days of their lives, including the requirement that services become Baby Friendly
accredited. It is possible to promote a healthy weight in the early years by taking 18 key actions,
including increasing investment in universal breastfeeding support, regulating misleading commercial
influences on infants and young children, and providing more assistance to families in introducing
solids and responding to feeding needs at an appropriate age (Unicef, 2022). In two longitudinal
studies, it was found that infant feeding mode (breastfeeding, mixed feeding, formula feeding) and
breastfeeding duration were associated with BMI z-score trajectory in early childhood, but not the
timing of solid food introduction. Based on these findings, extended breastfeeding can be encouraged
and supported as a method of preventing childhood obesity (Zheng et al., 2021). The WHO
commissioned a systematic review and meta-analysis of the association between breastfeeding and
overweight or obesity. Overall, 159 studies were assessed, concluding that breastfeeding was
associated with a reduction in overweight and obesity, and that publication bias and residual
confounding were unlikely to explain this association (Horta et al., 2022).

The modifications in the infants' formula, such as reducing the caloric content of standard infant
formula or adding milk fat globule membranes or altering the protein and fat content, may have some
benefits for infants who are exclusively formula fed, particularly early in life before the introduction
of complementary foods (Greer and Kleinman, 2014). A formula containing reduced energy and
protein density and supplemented with bovine milk fat globule membrane showed positive effects on
cognitive development and the incidence of acute otitis in infants without affecting body weight
parameters compared with standard formula (Timby et al., 2014;Timby et al., 2015).

The protein content in both formulas was within the range recommended by the EFSA after it proposed
to limit the maximum protein content of infant formulas to 2.5 g per 100 kcal. For infant formulas, it
is critical to consider the whey/casein ratio in addition to the total amount of protein (Martin et al.,
2016;Bohn et al., 2022). In the INN formula, the proportion of whey/casein was reduced to 70:30,
rather than 60:40 in the STD formula. Indeed, there was a higher concentration of α-lactalbumin, (20%)
compared to STD, which contains only 10%. There was no significant difference between the groups

in terms of length, head circumference, tricipital and subscapular skinfolds, and upper arm
circumference.

International expert consensus suggests that infant formulas that contain DHA at a concentration of
0.3% to 0.5% by weight of total fat and AA at a minimum level equivalent to the amount of DHA
should be clinically tested (Koletzko et al., 2020; Campoy et al., 2021). In this study, we used an
advanced formula enhanced with a double amount of DHA/AA in comparison with a STD formula to
provide evidence about weight gain and body composition, among other outcomes. Throughout the
study, the percentage of children with high tolerance increased without significant differences between
formulations and also compared to the group receiving BFD. According to the guardians or parents,
the infant's behavior was classified as altered mood or pleasant mood. There was a decrease in the
number of infants with altered behavior throughout the study. The three methods of feeding did not
show any significant differences.

National and sub-national governments regulate food safety and other issues relating to food, more or
less effectively. Globalization of the food system, however, necessitates guidance, monitoring, and
regulation at the global level. Especially for countries with little control over their own food systems,
which are vulnerable to pressures from outside, this is particularly true (Kent, 2015). In terms of the
intensity of adverse events, tolerability and safety, there were no differences between the different
groups (BFD, STD and INN formula). In different contexts and using different methods, infants are
fed a variety of products. The formula for infants is available in many variations, many of which are
superior to other methods of feeding and some of which are inferior to others. In the present study,
Bifidobacterium animalis subsp. *lactis* was added to the INN formula as a postbiotic (Carreras et al.,
2018;Nataraj et al., 2020), which may have some beneficial effects on body composition, metabolism,
and the composition of the gut microbiota (Carreras et al., 2018;Nataraj et al., 2020).

There was a significant difference between BFD infants presenting stools of a more liquid consistency,
although this difference no longer existed at visit five. As well, BFD infants had more stools per day
at visits 1, 2, and 3, but these differences ceased to be significant at visits 4 and 5. STD formula group
reported the most adverse events (291), followed by the INN formula (282) and BFD group (227).
There were no differences in safety across the study between the different groups. However, some
differences were observed between the two formulas, showing a significant reduction in general
disorders and disturbances among children who received the INN formula. STD formula-fed infants
were more likely to cause atopic dermatitis, bronchitis, and bronchiolitis than BFD or INN formula fed
infants. Changes in the formulation of the INN may have contributed to the decrease in adverse events.
Additionally, changes in the intestinal microbiota will need to be assessed.

In conclusion, this randomized, multicenter, double-blind, parallel and comparative clinical trial
involved the evaluation of a novel infant formula with reduced content of total protein and modification
of the whey/casein ratio by increasing the content of α-lactalbumin, increased levels of both AA and
DHA, and postbiotic in comparison with standard infant formula. For exploratory analysis, a third
unblinded group of breastfed infants was used. Both formulas gained more weight at 6 and 12 months
than the BFD group, while no difference was observed between STD and INN formulas. Infants fed
both formulas had a higher BMI than those fed BFD. Body composition, head circumference, and
tricipital/subscapular skinfolds were similar between the two groups in terms of length, head
circumference, and tricipital/subscapular skinfolds. We should note that the INN formula is safe and it
showed a reduction in atopic dermatitis, bronchitis, and bronchiolitis in infants compared to STD
formula. The consistency of the stools produced by BDF was more liquid in comparison with both
formulas. Each group demonstrated similar digestive tolerance and infant behavior throughout the

study period. For further analysis, it would be necessary to examine more precise health biomarkers including those derived from the omics sciences, e.g. metabolomics, proteomics, metagenomics, etc., to determine to what extent there are significant differences between treatments, beyond growth parameters.

Conflict of Interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Author Contributions

AGG, IG and MM were responsible for a careful review of the protocol, design, and methodology. FJRO, JPD and AG provided continuous scientific advice for the study and the interpretation of the results. These authors also wrote and critically reviewed the manuscript. All authors approved the final version of the manuscript.

Funding

The present study was funded by Alter Farmacia S. A. The funding sponsor had no role in the design of the study, the collection, analysis, or interpretation of the data, and the writing of the manuscript.

Acknowledgments

We thank to the pediatrician team who participated in this study: Alba Corrales; Alfonso Carmona; Amalia López; Ana Isabel Rodriguez; Ana Maderuelo; Ana Terrén-Lora, Carlos Nuñez de Prado; Eduardo Ortega; Esther Martin; Eva Castillo; Isabel Mayordomo; José Fernando Ferreira; José María Aguilar Diosdado; Maite Santos-Garcia; Mari Carmen Pino Zambrano; María José Carnicero; Maria Teresa Santos; Vasilica Doina and Xavier Riopedre.

Supplementary Material

Supplementary material is expressed as tables and is found in the supplemtary file (Tables S1-S5).

Data Availability Statement

The datasets used and/or analyzed during the current study are available from the corresponding author upon reasonable request.

References

Adjibade, M., Davisse-Paturet, C., Divaret-Chauveau, A., Adel-Patient, K., Raherison, C., Dufourg, M.N., Lioret, S., Charles, M.A., and De Lauzon-Guillain, B. (2022). Enrichment of Formula in Probiotics or Prebiotics and Risk of Infection and Allergic Diseases up to Age 5.5 Years in the Nationwide Etude Longitudinale Francaise depuis l'Enfance (ELFE) Cohort. *J Nutr* 152**,** 1138-1148.

Balaguer, F., Enrique, M., Llopis, S., Barrena, M., Navarro, V., Alvarez, B., Chenoll, E., Ramon, D., Tortajada, M., and Martorell, P. (2022). Lipoteichoic acid from Bifidobacterium animalis subsp. lactis BPL1: a novel postbiotic that reduces fat deposition via IGF-1 pathway. *Microb Biotechnol* 15**,** 805-816.

Balogun, O.O., Dagvadorj, A., Anigo, K.M., Ota, E., and Sasaki, S. (2015). Factors influencing
breastfeeding exclusivity during the first 6 months of life in developing countries: a
quantitative and qualitative systematic review. *Maternal & child nutrition* 11**,** 433-451.

Bell, K.A., Wagner, C.L., Feldman, H.A., Shypailo, R.J., and Belfort, M.B. (2017). Associations of
infant feeding with trajectories of body composition and growth. *Am J Clin Nutr* 106**,** 491-
498.

Black, R.E., Victora, C.G., Walker, S.P., Bhutta, Z.A., Christian, P., De Onis, M., Ezzati, M.,
Grantham-Mcgregor, S., Katz, J., and Martorell, R. (2013). Maternal and child undernutrition
and overweight in low-income and middle-income countries. *The lancet* 382**,** 427-451.

Bohn, T., Castenmiller, J., De Henauw, S., Hirsch-Ernst, K.-I., Knutsen, H.K., Maciuk, A.,
Mangelsdorf, I., Mcardle, H.J., Naska, A., Pelaez, C., Pentieva, K., Siani, A., Thies, F.,
Tsabouri, M.V., Bresson, J.-L., Castle, L., Fewtrell, M., Przyrembel, H., Dumas, C., Titz, A.,
and Turck, D. (2022). Nutritional safety and suitability of a specific protein hydrolysate
derived from whey protein concentrate and used in an infant and follow-on formula
manufactured from hydrolysed protein by HIPP-Werk Georg Hipp OHG (dossier submitted
by meyer.science GmbH). *EFSA Journal* 20**,** 1-13.

Braegger, C., Chmielewska, A., Decsi, T., Kolacek, S., Mihatsch, W., Moreno, L., Piescik, M.,
Puntis, J., Shamir, R., Szajewska, H., Turck, D., Van Goudoever, J., and Nutrition, E.C.O.
(2011). Supplementation of infant formula with probiotics and/or prebiotics: a systematic
review and comment by the ESPGHAN committee on nutrition. *J Pediatr Gastroenterol Nutr*
52**,** 238-250.

Brands, B., Demmelmair, H., Koletzko, B., and Project, E. (2014). How growth due to infant
nutrition influences obesity and later disease risk. *Acta paediatrica* 103**,** 578-585.

Campoy, C., Am, C.T., De La Garza Puentes, A., Sáenz De Pipaón, M., Verduci, E., Koletzko, B.,
Casanova, G., Larqué, E., Valenzuela, R., and Jm, M.V. (2021). Controversy about the
critical role of long-chain polyunsaturated fatty acids, arachidonic acid (ARA) and
docosahexaenoic acid (DHA), during infancy. *Nutricion Hospitalaria*.

Carreras, N.L., Martorell, P., Chenoll, E., Genoves, S., Ramon, D., and Aleixandre, A. (2018). Anti-
obesity properties of the strain Bifidobacterium animalis subsp. lactis CECT 8145 in Zucker
fatty rats. *Benef Microbes* 9**,** 629-641.

Carver, J.D. (2003). Advances in nutritional modifications of infant formulas. *The American journal*
of clinical nutrition 77**,** 1550S-1554S.

Christian, P., Smith, E.R., Lee, S.E., Vargas, A.J., Bremer, A.A., and Raiten, D.J. (2021). The need
to study human milk as a biological system. *Am J Clin Nutr* 113**,** 1063-1072.

Codex Alimentaris (2020). *STANDARD FOR INFANT FORMULA AND FORMULAS FOR*
SPECIAL MEDICAL PURPOSES INTENDED FOR INFANTS. Formerly CAC/RS 72-1972.
Adopted as a worldwide Standard in 1981. Amended in 1983, 1985, 1987, 2011, 2015, 2016,
2020. Revised in 2007. [Online]. Available: https://www.fao.org/fao-who-
codexalimentarius/sh-
proxy/es/?lnk=1&url=https%253A%252F%252Fworkspace.fao.org%252Fsites%252Fcodex
%252FStandards%252FCXS%2B72-1981%252FCXS_072e.pdf [Accessed 2022-06-12].

Dieterich, C.M., Felice, J.P., O'sullivan, E., and Rasmussen, K.M. (2013). Breastfeeding and health
outcomes for the mother-infant dyad. *Pediatr Clin North Am* 60**,** 31-48.

Efsa Panel on Dietetic Products, N., and Allergies (2014). Scientific Opinion on the essential
composition of infant and follow-on formulae. *EFSA Journal* 12**,** 3760.

Eidelman, A.I., Schanler, R.J., Johnston, M., Landers, S., Noble, L., Szucs, K., and Viehmann, L.
(2012). Breastfeeding and the use of human milk. *Pediatrics* 129**,** e827-841.

Eu Commission (2016). Commission Delegated Regulation (EU) 2016/127 of 25 September 2015
supplementing Regulation (EU) No 609/2013 of the European Parliament and of the Council
as regards the specific compositional and information requirements for infant formula and
follow-on formula and as regards requirements on information relating to infant and young
child feeding. *OJEC* 59**,** 1-29.

Flaherman, V.J., Narayan, N.R., Hartigan-O'connor, D., Cabana, M.D., Mcculloch, C.E., and Paul,
I.M. (2018). The effect of early limited formula on breastfeeding, readmission, and intestinal
microbiota: a randomized clinical trial. *The Journal of pediatrics* 196**,** 84-90. e81.

Food and Drug Administration, F. (2018). *Infant formula requirements pertaining to current good*
manufacturing practice, quality control procedures, quality factors, records and reports and
notifications. [Online]. Available:
https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=106
[Accessed 2022-06-12].

Gopalakrishna, K.P., and Hand, T.W. (2020). Influence of Maternal Milk on the Neonatal Intestinal
Microbiome. *Nutrients* 12.

Greer, F.R., and Kleinman, R.E. (2014). An infant formula with decreased weight gain and higher
IQ: are we there yet? *Am J Clin Nutr* 99**,** 757-758.

Horta, B.L., Rollins, N., Dias, M.S., Garcez, V., and Pérez-Escamilla, R. (2022). Systematic review
and meta-analysis of breastfeeding and later overweight or obesity expands on previous study
for World Health Organization. *Acta Paediatrica*.

Ip, S., Chung, M., Raman, G., Trikalinos, T.A., and Lau, J. (2009). A summary of the Agency for
Healthcare Research and Quality's evidence report on breastfeeding in developed countries.
Breastfeed Med 4 Suppl 1**,** S17-30.

Jama, A., Gebreyesus, H., Wubayehu, T., Gebregyorgis, T., Teweldemedhin, M., Berhe, T., and
Berhe, N. (2020). Exclusive breastfeeding for the first six months of life and its associated
factors among children age 6-24 months in Burao district, Somaliland. *Int Breastfeed J* 15**,** 5.

Kent, G. (2015). Global infant formula: monitoring and regulating the impacts to protect human
health. *Int Breastfeed J* 10**,** 6.

Koletzko, B., Baker, S., Cleghorn, G., Neto, U.F., Gopalan, S., Hernell, O., Hock, Q.S., Jirapinyo, P.,
Lonnerdal, B., Pencharz, P., Pzyrembel, H., Ramirez-Mayans, J., Shamir, R., Turck, D.,
Yamashiro, Y., and Zong-Yi, D. (2005). Global standard for the composition of infant
formula: recommendations of an ESPGHAN coordinated international expert group. *J*
Pediatr Gastroenterol Nutr 41**,** 584-599.

Koletzko, B., Bergmann, K., Brenna, J.T., Calder, P.C., Campoy, C., Clandinin, M.T., Colombo, J.,
Daly, M., Decsi, T., and Demmelmair, H. (2020). Should formula for infants provide
arachidonic acid along with DHA? A position paper of the European Academy of Paediatrics
and the Child Health Foundation. *The American journal of clinical nutrition* 111**,** 10-16.

Koletzko, B., Von Kries, R., Closa, R., Escribano, J., Scaglioni, S., Giovannini, M., Beyer, J.,
Demmelmair, H., Gruszfeld, D., Dobrzanska, A., Sengier, A., Langhendries, J.-P., Rolland

Cachera, M.-F., Grote, V., and European Childhood Obesity Trial Study Group (2009). Lower protein in infant formula is associated with lower weight up to age 2 y: a randomized clinical trial. *The American journal of clinical nutrition* 89**,** 1836-1845.

Libuda, L., Stimming, M., Mesch, C., Warschburger, P., Kalhoff, H., Koletzko, B.V., and Kersting, M. (2014). Frequencies and demographic determinants of breastfeeding and DHA supplementation in a nationwide sample of mothers in Germany. *European journal of nutrition* 53**,** 1335-1344.

Martin, C.R., Ling, P.R., and Blackburn, G.L. (2016). Review of Infant Feeding: Key Features of Breast Milk and Infant Formula. *Nutrients* 8.

Meddra, M. (2018). "Introductory Guide for Standardised MedDRA Queries (SMQs) Version 21.0".).

Monasta, L., Batty, G., Macaluso, A., Ronfani, L., Lutje, V., Bavcar, A., Van Lenthe, F., Brug, J., and Cattaneo, A. (2011). Interventions for the prevention of overweight and obesity in preschool children: a systematic review of randomized controlled trials. *Obesity reviews* 12**,** e107-e118.

Nataraj, B.H., Ali, S.A., Behare, P.V., and Yadav, H. (2020). Postbiotics-parabiotics: the new horizons in microbial biotherapy and functional foods. *Microb Cell Fact* 19**,** 168.

Ogbu, C.E., Fongue, S., Ogbu, S.C., and Kirby, R.S. (2021). Infant feeding practices and asthma in children aged 6 months to 5 years using a propensity score approach. *Cent Eur J Public Health* 29**,** 284-289.

Papadopoulos, N.G., Balan, T.A., Van Der Merwe, L.F., Pang, W.W., Michaelis, L.J., Shek, L.P., Vandenplas, Y., Teoh, O.H., Fiocchi, A.G., and Chong, Y.S. (2022). Mixed Milk Feeding: A New Approach to Describe Feeding Patterns in the First Year of Life Based on Individual Participant Data from Two Randomised Controlled Trials. *Nutrients* 14**,** 2190.

Pedret, A., Valls, R.M., Calderon-Perez, L., Llaurado, E., Companys, J., Pla-Paga, L., Moragas, A., Martin-Lujan, F., Ortega, Y., Giralt, M., Caimari, A., Chenoll, E., Genoves, S., Martorell, P., Codoner, F.M., Ramon, D., Arola, L., and Sola, R. (2019). Effects of daily consumption of the probiotic Bifidobacterium animalis subsp. lactis CECT 8145 on anthropometric adiposity biomarkers in abdominally obese subjects: a randomized controlled trial. *Int J Obes (Lond)* 43**,** 1863-1868.

Rameez, R.M., Sadana, D., Kaur, S., Ahmed, T., Patel, J., Khan, M.S., Misbah, S., Simonson, M.T., Riaz, H., and Ahmed, H.M. (2019). Association of Maternal Lactation With Diabetes and Hypertension: A Systematic Review and Meta-analysis. *JAMA Netw Open* 2**,** e1913401.

Rollins, N.C., Bhandari, N., Hajeebhoy, N., Horton, S., Lutter, C.K., Martines, J.C., Piwoz, E.G., Richter, L.M., Victora, C.G., and Group, T.L.B.S. (2016). Why invest, and what it will take to improve breastfeeding practices? *The lancet* 387**,** 491-504.

Ruiz-Ojeda, F.J., Plaza-Diaz, J., Morales, J., De La Torre, A.I.C., Garcia-Garcia, A., De Prado, C.N., Coronel, C., Crespo, C., Ortega, E., and Martin-Perez, E. (2022). A multicenter, randomized, blinded, controlled clinical trial investigating the effect of a novel infant formula on the body composition of infants: INNOVA 2020 study protocol. *medRxiv*.

Salminen, S., Collado, M.C., Endo, A., Hill, C., Lebeer, S., Quigley, E.M.M., Sanders, M.E., Shamir, R., Swann, J.R., Szajewska, H., and Vinderola, G. (2021). The International Scientific

779   Association of Probiotics and Prebiotics (ISAPP) consensus statement on the definition and
780   scope of postbiotics. *Nat Rev Gastroenterol Hepatol* 18**,** 649-667.

781 Scott, J.A., Binns, C.W., Oddy, W.H., and Graham, K.I. (2006). Predictors of breastfeeding duration:
782   evidence from a cohort study. *Pediatrics* 117**,** e646-e655.

783 Silva, A., Gonzalez, N., Terren, A., Garcia, A., Martinez-Blanch, J.F., Illescas, V., Morales, J.,
784   Maroto, M., Genoves, S., Ramon, D., Martorell, P., and Chenoll, E. (2020). An Infant Milk
785   Formula Supplemented with Heat-Treated Probiotic Bifidobacterium animalis subsp. lactis
786   CECT 8145, Reduces Fat Deposition in C. elegans and Augments Acetate and Lactate in a
787   Fermented Infant Slurry. *Foods* 9.

788 Szajewska, H., Canani, R.B., Guarino, A., Hojsak, I., Indrio, F., Kolacek, S., Orel, R., Shamir, R.,
789   Vandenplas, Y., Van Goudoever, J.B., Weizman, Z., and Probioticsprebiotics, E.W.G.F.
790   (2016). Probiotics for the Prevention of Antibiotic-Associated Diarrhea in Children. *J Pediatr*
791   *Gastroenterol Nutr* 62**,** 495-506.

792 Task Force on Clinical Testing of Infant Formulas Committee on Nutrition. American Academy of
793   Pediatrics Committee on Nutrition, L, F., Bell Ef, Cooke Rj, Fomon Sj, Kleinman Re,
794   Pencharz Pb, Reynolds Jw, Schanler Rj, and Al, F. (1988). *Clinical Testing of Infant*
795   *Formulas With Respect to Nutritional Suitability for Term Infants* [Online]. Available:
796   https://wayback.archive-
797   it.org/7993/20170722090324/https://www.fda.gov/Food/GuidanceRegulation/GuidanceDocu
798   mentsRegulatoryInformation/InfantFormula/ucm170649.htm [Accessed 2022-06-24].

799 Thomas, D.W., Greer, F.R., American Academy of Pediatrics Committee On, N., American
800   Academy of Pediatrics Section on Gastroenterology, H., and Nutrition (2010). Probiotics and
801   prebiotics in pediatrics. *Pediatrics* 126**,** 1217-1231.

802 Timby, N., Domellof, E., Hernell, O., Lonnerdal, B., and Domellof, M. (2014). Neurodevelopment,
803   nutrition, and growth until 12 mo of age in infants fed a low-energy, low-protein formula
804   supplemented with bovine milk fat globule membranes: a randomized controlled trial. *Am J*
805   *Clin Nutr* 99**,** 860-868.

806 Timby, N., Hernell, O., Vaarala, O., Melin, M., Lonnerdal, B., and Domellof, M. (2015). Infections
807   in infants fed formula supplemented with bovine milk fat globule membranes. *J Pediatr*
808   *Gastroenterol Nutr* 60**,** 384-389.

809 Unicef, U.K. (2022). *OVERWEIGHT AND OBESITY INFANT HEALTH RESEARCH* [Online].
810   UNICEF. Available: https://www.unicef.org.uk/babyfriendly/news-and-research/baby-
811   friendly-research/infant-health-research/infant-health-research-obesity/ [Accessed 2022-08-31
812   2022].

813 Victora, C.G., Bahl, R., Barros, A.J., França, G.V., Horton, S., Krasevec, J., Murch, S., Sankar, M.J.,
814   Walker, N., and Rollins, N.C. (2016). Breastfeeding in the 21st century: epidemiology,
815   mechanisms, and lifelong effect. *The lancet* 387**,** 475-490.

816 Vinderola, G., Sanders, M.E., and Salminen, S. (2022). The Concept of Postbiotics. *Foods* 11.

817 Walker, A. (2010). Breast milk as the gold standard for protective nutrients. *J Pediatr* 156**,** S3-7.

818 Wallingford, J.C., and Barber, C. (2019). A review of studies on the growth of infants fed infant
819   formula. *Current Developments in Nutrition* 3**,** nzz095.

World Health Organization (2002). *The optimal duration of exclusive breastfeeding: a systematic*
review [Online]. Available:
https://apps.who.int/iris/bitstream/handle/10665/67208/WHO_NHD_01.08.pdf [Accessed].

World Health Organization (2022). *World Health Organization breastfeeding recommendations*
[Online]. Available: https://www.who.int/health-topics/breastfeeding/ [Accessed 2022-06-
12].

Zheng, M., Campbell, K.J., Baur, L., Rissel, C., and Wen, L.M. (2021). Infant feeding and growth
trajectories in early childhood: the application and comparison of two longitudinal modelling
approaches. *Int J Obes (Lond)* 45**,** 2230-2237.

Zheng, M., Lamb, K.E., Grimes, C., Laws, R., Bolton, K., Ong, K.K., and Campbell, K. (2018).
Rapid weight gain during infancy and subsequent adiposity: A systematic review and meta-
analysis of evidence. *Obesity Reviews* 19**,** 321-332.

Ziegler, E.E. (2006). Growth of breast-fed and formula-fed infants. *Nestle Nutr Workshop Ser*
Pediatr Program 58**,** 51-59; discussion 59-63.